Pharmaceuticals

Drug costs at pharmacies lack transparency

Drug costs at pharmacies lack transparency

Statute needed to require patients be informed of cheaper alternatives

AS A PRACTICING PHYSICIAN, nearly every time I write a prescription, I have to ask myself: “Will this patient be able to afford this at the beginning of the calendar year when they have not yet met their deductible? Will they be able to afford this medicine in the middle of the calendar year when(...)

Read More »

Cost barriers rise for patients

Cost barriers rise for patients

Insurance deductible policies for drugs hurt those most in need

THERE SEEMS TO be a new story each day about how patients across the country are being treated unfairly by their health insurance company. Chances are, you or someone you love has been through something like this. These are patients who have done the right thing, worked hard, paid their premiums, and expected that when(...)

Read More »

Taxpayers clean up Big Pharma’s mess

Taxpayers clean up Big Pharma’s mess

States must take action to force manufacturers to pay for disposal of unused drugs

LAST YEAR, the United States saw a 13 percent increase in drug overdose deaths, from an estimated 60,147 lives lost in 2016, to an estimated 67,944 in 2017. For perspective, that is enough to completely fill Gillette Stadium, with an overflow of 2,066 individuals. Here in Massachusetts, we experienced a slight decrease in opioid related(...)

Read More »

Big Pharma hides costs with bait and switch

Big Pharma hides costs with bait and switch

Drug companies offer copay breaks to get big insurance payments

THE ADS FOR high-end prescription drugs seem ubiquitous. Invokana, Xarelto, Abilify, and Humira are just a few names familiar to anyone with a television. The drugs are some of the stars of the more than $5 billion in direct-to-consumer advertising the pharmaceutical industry does each year to convince patients to ask their doctors to prescribe(...)

Read More »

Senate President pushes drug bulk purchasing

Senate President pushes drug bulk purchasing

Rosenberg wants to pool buying power with other states

CONCERNED ABOUT THE RISING COST of pharmaceuticals, Senate President Stanley Rosenberg is pushing a budget proposal that would direct the state to use bulk purchasing to negotiate lower prices with drug manufacturers. The proposal builds on a House budget measure authorizing the state to purchase the drug naxalone, often marketed under the brand name Narcan,(...)

Read More »